{
    "Trade/Device Name(s)": [
        "Eocene Glucose Telecommunication System",
        "GLUCOLAB Diabetes Monitoring System",
        "EOCENE System",
        "GlucoLab Brand System",
        "Eclipse Diabetes Monitoring System"
    ],
    "Submitter Information": "Infopia Co., Ltd.",
    "510(k) Number": "K090712",
    "Predicate Device Reference 510(k) Number(s)": [
        "K051285"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "JQP"
    ],
    "Summary Letter Date": "Sep 2, 2009",
    "Summary Letter Received Date": "Sep 3, 2009",
    "Submission Date": "March 2009",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 862.1660",
        "21 CFR 870.2910"
    ],
    "Regulation Name(s)": [
        "Glucose test system",
        "Data management system; Accessory to medical device",
        "Physiological signal transmitters and receivers"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Capillary Whole Blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Eocene cradle",
        "GLUCOLAB Diabetes Monitoring System",
        "EOCENE System",
        "Eclipse Diabetes Monitoring System"
    ],
    "Method(s)/Technology(ies)": [
        "Glucose oxidase"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Accessory",
        "Analyzer",
        "Monitoring System"
    ],
    "Document Summary": "FDA 510(k) summary for Infopia Co., Ltd. Eocene Glucose Telecommunication System and GLUCOLAB Diabetes Monitoring System for quantitative glucose measurement and remote data management",
    "Indications for Use Summary": "For quantitative measurement of glucose level in capillary whole blood as an aid in monitoring effectiveness of diabetes management in home and clinical settings; not for diagnosis, screening, or neonatal use; for in vitro diagnostic use only with multiple alternate testing sites.",
    "fda_folder": "Clinical Chemistry"
}